NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Friday:
Blue Bird Corp., up $7.01 to $26.33.
The school bus maker beat Wall Street's fiscal second-quarter earnings and revenue forecasts.
Telesis Bio, Inc., down 35 cents to $2.53.
The synthetic biology company reported disappointing first-quarter revenue.
Harrow Health, Inc., down $5.03 to $ 22.04.
The make of ophthalmological pharmaceuticals reported a bigger first-quarter loss than analysts expected.
News Corp., up $1.46 to $18.29.
The publisher of The Wall Street Journal beat analysts' fiscal third-quarter profit and revenue forecasts.
Agile Therapeutics Inc., down 68 cents to $5.
The developer of prescription contraceptive products for women reported disappointing first-quarter earnings.
Spectrum Brands Holdings Inc., down 64 cents to $70.70.
The maker of Nature's Miracle and other household products reported weak second-quarter revenue.
First Solar Inc., up $48.50 to $231.69.
The solar technology company is buying Sweden’s Evolar.
IonQ Inc., down 67 cents to $6.35.
The quantum computing technology company reported weak first-quarter earnings.
Before you consider Telesis Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telesis Bio wasn't on the list.
While Telesis Bio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
